Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis

Ann Rheum Dis. 2021 Dec;80(12):1635-1638. doi: 10.1136/annrheumdis-2021-220862. Epub 2021 Jun 25.

Serena Bugatti^{1

2}, Ludovico De Stefano^{3

2}, Silvia Balduzzi³, Maria Immacolata Greco³, Terenzj Luvaro³, Irene Cassaniti^{4

5}, Laura Bogliolo³, Iolanda Mazzucchelli², Bernardo D'Onofrio^{3

2}, Michele di Lernia^{3

2}, Eleonora Mauric^{3

2}, Daniele Lilleri⁴, Fausto Baldanti^{4

5}, Antonio Manzo^{3

2}, Carlomaurizio Montecucco^{3

2}

¹ Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy serena.bugatti@unipv.it.
² Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
³ Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
⁴ Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
⁵ Department of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia, Italy.

No abstract available

Keywords: COVID-19; biological therapy; glucocorticoids; methotrexate; vaccination.

Publication types